Homeostatic bioenergetic network regulation: A novel concept to avoid pharmacoresistance in epilepsy

Expert Opinion on Drug Discovery

Volumn 6, Issue 7, 2011, Pages 713-724

  Boison, Detlev ^a   Masino, Susan A ^b   Geiger, Jonathan D ^c  

^a LEGACY RESEARCH   (United States)

^b TRINITY COLLEGE   (United States)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

adenosine; brain homeostasis; drug resistance; epilepsy; gene therapy; stem cells

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; DIAZEPAM; GLYCOPROTEIN P; METHYLXANTHINE; PHENOBARBITAL; PHENYTOIN; TARIQUIDAR; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; BIOENERGY; BLOOD BRAIN BARRIER; BRAIN ELECTROPHYSIOLOGY; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; EPILEPSY; EPILEPTIC STATE; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; KETOGENIC DIET; LETHARGY; NEPHROLITHIASIS; NONHUMAN; PHARMACOGENETICS; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SILK; TEMPORAL LOBE EPILEPSY;

EID: 79959485867     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.575777     Document Type: Review

References (101)

1. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9(1):68-82
2. Vajda FJE. Pharmacotherapy of epilepsy: new armamentarium, new issues. J Clin Neurosci 2007;6(9):813-23 (Pubitemid 47095340)
3. Qureshi IA, Mehler MF. Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis. Neurobiol Dis 2010;39(1):53-60
4. Cymerblit-Sabba A, Schiller Y. Network dynamics during development of pharmacologically induced epileptic seizures in rats in vivo. J Neurosci 2010;30(5):1619-30
5. Roopun AK, Simonotto JD, Pierce ML, et al. A nonsynaptic mechanism underlying interictal discharges in human epileptic neocortex. Proc Natl Acad Sci USA 2010;107(1):338-43
6. Vezzani A, Ravizza T, Balosso S, et al. Glia as a source of cytokines: implications for neuronal excitability and survival. Epilepsia 2008;49(Suppl 2):24-32 (Pubitemid 351143763)
7. Ravizza T, Gagliardi B, Noe F, et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008;29(1):142-60 (Pubitemid 350180489)
8. Lazarowski A, Czornyj L, Lubienieki F, et al. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007;48(Suppl 5):140-9 (Pubitemid 47512215)
9. Seifert G, Carmignoto G, Steinhauser C. Astrocyte dysfunction in epilepsy. Brain Res Rev 2010;63(1-2):212-21
10. Rouach N, Koulakoff A, Abudara V, et al. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 2008;322(5907):1551-5
11. Aronica E, Fluiter K, Iyer A, et al. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci 2010;31:1100-07
12. Jandova K, Pasler D, Antonio LL, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain 2006;129(Pt 12):3290-306 (Pubitemid 44871443)
13. Bethmann K, Fritschy JM, Brandt C, et al. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis 2008;31(2):169-87
14. Volk HA, Arabadzisz D, Fritschy JM, et al. Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegene and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol Dis 2006;21(3):633-46 (Pubitemid 43277545)
15. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006;5(3):246-56 (Pubitemid 43238348)
16. Schaub C, Uebachs M, Beck H. Diminished response of CA1 neurons to antiepileptic drugs in chronic epilepsy. Epilepsia 2007;48(7):1339-50 (Pubitemid 47063089)
17. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006;129(Pt 1):18-35 (Pubitemid 43063756)
18. Heinemann U, Kann O, Remy S, et al. Novel mechanisms underlying drug resistance in temporal lobe epilepsy. Adv Neurol 2006;97:85-95
19. Loscher W. How to explain multidrug resistance in epilepsy? Epilepsy Curr 2005;5(3):107-12
20. Loscher W. Drug transporters in the epileptic brain. Epilepsia 2007;48(Suppl 1):8-13 (Pubitemid 46280513)
21. Ak H, Ay B, Tanriverdi T, et al. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure 2007;16(6):493-503 (Pubitemid 47209238)
22. Kubota H, Ishihara H, Langmann T, et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006;68(3):213-28
23. Liu X, Yang Z, Yang J, et al. Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 2007;53(5):657-63 (Pubitemid 47513172)
24. Hoffmann K, Gastens AM, Volk HA, et al. Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res 2006;69(1):1-14
25. Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005;53(4):517-31 (Pubitemid 40463506)
26. Volk HA, Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005;128(Pt 6):1358-68 (Pubitemid 40826189)
27. van Vliet EA, van Schaik R, Edelbroek PM, et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007;322(1):141-7 (Pubitemid 46956371)
28. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6(8):591-602 (Pubitemid 41059334)
29. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005;76(1):22-76 (Pubitemid 41033402)
30. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2(1):86-98 (Pubitemid 40128029)
31. Brandt C, Bethmann K, Gastens AM, et al. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006;24(1):202-11 (Pubitemid 44416217)
32. van Vliet EA, van Schaik R, Edelbroek PM, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006;47(4):672-80
33. van Vliet EA, Zibell G, Pekcec A, et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010;58(2):404-12
34. Cucullo L, Hossain M, Rapp E, et al. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007;48(3):505-16 (Pubitemid 46365189)
35. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008;55(8):1364-75
36. Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008;8(5):127-30
37. Sillanpaa M, Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain 2008;131(Pt 4):938-44 (Pubitemid 351499433)
38. Sillanpaa M, Schmidt D. Delayed time to first remission identifies poor long-term drug response of childhood-onset epilepsy: a prospective population-based study. Epilepsy Behav 2009;16(3):507-11
39. Sillanpaa M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 2009;132(Pt 4):989-98
40. Spooner CG, Berkovic SF, Mitchell LA, et al. New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome. Neurology 2006;67(12):2147-53 (Pubitemid 46035466)
41. Loscher W, Klotz U, Zimprich F, et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50(1):1-23
42. Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit 2007;29(3):305-12 (Pubitemid 47262260)
43. Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008;17(6):524-30
44. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010;51(1):7-26
45. Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006;47(11):1761-74 (Pubitemid 44730046)
46. Marchi N, Teng Q, Ghosh C, et al. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brai Res 2010;1353:176-86
47. Wahab A, Albus K, Gabriel S, et al. In search of models of pharmacoresistant epilepsy. Epilepsia 2010;51(Suppl 3):154-9
48. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 2010;51(8):1333-47
49. Nabbout R, Vezzani A, Dulac O, et al. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol 2011;10(1):99-108
50. Granata T, Marchi N, Carlton E, et al. Management of the patient with medically refractory epilepsy. Expert Rev Neurother 2009;9(12):1791-802
51. Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007;52(2):589-93 (Pubitemid 46202845)
52. Ruskin DN, Kawamura M, Masino SA. Reduced pain and inflammation in juvenile and adult rats fed a ketogenic diet. PLoS One 2009;4(12):e8349
53. Chen X, Lan X, Roche I, et al. Caffeine protects against MPTP-induced bloodbrain barrier dysfunction in mouse striatum. J Neurochem 2008;107(4):1147-57
54. Chen X, Gawryluk JW, Wagener JF, et al. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflamm 2008;5:12
55. Masino SA, Geiger JD. Are purines mediators of the anticonvulsant/ neuroprotective effects of ketogenic diets? Trends Neurosci 2008;31(6):273-78
56. Tchekalarova J, Kubova H, Mares P. Postnatal caffeine treatment affects differently two pentylenetetrazol seizure models in rats. Seizure 2009;18(7):463-9
57. Boison D. Methylxanthines, seizures and excitotoxicity. Handb Exp Pharmacol 2010;200:251-66
58. Oberheim NA, Tian GF, Han X, et al. Loss of astrocytic domain organization in the epileptic brain. J Neurosci 2008;28(13):3264-76 (Pubitemid 351469330)
59. Binder DK, Steinhauser C. Functional changes in astroglial cells in epilepsy. Glia 2006;54(5):358-68 (Pubitemid 44422938)
60. Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007;13(2):54-63 (Pubitemid 46186152)
61. Iyer AM, Zurolo E, Boer K, et al. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Neuroscience 2010;167(3):929-45
62. Williamson A, Patrylo PR, Pan J, et al. Correlations between granule cell physiology and bioenergetics in human temporal lobe epilepsy. Brain 2005;128(Pt 5):1199-208 (Pubitemid 40675473)
63. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009;8(11):1056-72
64. Karagiannis TC, Kn H, El-Osta A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 2006;1(3):131-7
65. Miller SL, Urey HC. Organic compound synthesis on the primitive earth. Science 1959;130:245-51
66. Mato JM, Martinez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr 2008;28:273-93
67. Boison D, Scheurer L, Zumsteg V, et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci USA 2002;99(10):6985-90 (Pubitemid 34526244)
68. Studer FE, Fedele DE, Marowsky A, et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006;142(1):125-37 (Pubitemid 44353936)
69. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 2005;11(1):25-36 (Pubitemid 40223088)
70. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009;193:535-87
71. Cunha RA. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal 2005;1:111-34 (Pubitemid 40466898)
72. Li T, Ren G, Lusardi T, et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Inv 2008;118(2):571-82 (Pubitemid 351206547)
73. Fedele DE, Li T, Lan JQ, et al. Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 2006;200(1):184-90 (Pubitemid 44080760)
74. Sebastiao AM, Ribeiro JA. Tuning and fine-tuning of synapses with adenosine. Curr Neuropharmacol 2009;7(3):180-94
75. Chen JF, Sonsalla PK, Pedata F, et al. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 2007;83(5):310-31 (Pubitemid 350119825)
76. Malhotra J, Gupta YK. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rats. Br J Pharmacol 1997;120(2):282-8 (Pubitemid 27039278)
77. Zeraati M, Mirnajafi-Zadeh J, Fathollahi Y, et al. Adenosine A(1) and A(2A) receptors of hippocampal CA1 region have opposite effects on piriform cortex kindled seizures in rats. Seizure Eur J Epilepsy 2006;15(1):41-8 (Pubitemid 43092094)
78. Cunha RA. Different cellular sources and different roles of adenosine: A(1) receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A(2A) receptor-mediated facilitation of plasticity. Neurochem Int 2008;52(1-2):65-72 (Pubitemid 350235700)
79. Hasko G, Pacher P, Vizi ES, et al. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 2005;26(10):511-16 (Pubitemid 41338561)
80. El Yacoubi M, Ledent C, Parmentier M, et al. Adenosine A2A receptor deficient mice are partially resistant to limbic seizures. Naunyn Schmiedebergs Arch Pharmacol 2009;380(3):223-32
81. Czuczwar SJ, Szczepanik B, Wamil A, et al. Differential effects of agents enhancing purinergic transmission upon the antielectroshock efficacy of carbamazepine, diphenylhydantoin, diazepam, phenobarbital, and valproate in mice. J Neural Transm Gen Sect 1990;81(2):153-66 (Pubitemid 20175070)
82. De Sarro G, De Sarro A, Di Paola ED, et al. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur J Pharmacol 1999;371(2-3):137-45 (Pubitemid 29216995)
83. von Lubitz DKJE, Carter MF, Deutsch SI, et al. The effects of adenosine A3 receptor stimulation on seizures in mice. Eur J Pharmacol 1995;275(1):23-9
84. Borowicz KK, Kleinrok Z, Czuczwar SJ. N6-2-(4-aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol 1997;327(2-3):125-33 (Pubitemid 27248536)
85. Lado FA, Moshe SL. How do seizures stop? Epilepsia 2008;49(10):1651-64
86. Pignataro G, Simon RP, Boison D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab 2007;27(1):1-5 (Pubitemid 46006578)
87. Gouder N, Scheurer L, Fritschy J-M, et al. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci 2004;24(3):692-701 (Pubitemid 38166495)
88. Borowicz KK, Luszczki J, Czuczwar SJ. 2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anticonvulsant activity of carbamazepine and clonazepam in mice. Eur Neuropsychopharmacol 2002;12(2):173-9 (Pubitemid 34168483)
89. Luszczki JJ, Kozicka M, Swiader MJ, et al. 2-Chloro-N-6- cyclopentyladenosine enhances the anticonvulsant action of carbamazepine in the mouse maximal electroshock-induced seizure model(A). Pharmacol Rep 2005;57(6):787-94
90. Kossoff EH, Zupec-Kania BA, Rho JM. Ketogenic Diets: an update for child neurologists. J Child Neurol 2009;24(8):979-88
91. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008;7(6):500-6
92. Kawamura M Jr, Ruskin DN, Masino SA. Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors, and KATP channels. J Neurosci 2010;30(11):3886-95
93. Kossoff EH, Rowley H, Sinha SR, et al. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 2008;49(2):316-19 (Pubitemid 351171986)
94. Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009;50(2):304-17
95. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol 2010;52(11):988-93
96. Kossoff EH, Hedderick EF, Turner Z, et al. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia 2008;49(9):1504-9
97. Wilz A, Pritchard EM, Li T, et al. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008;29(26):3609-16
98. Vepari C, Kaplan DL. Silk as a biomaterial. Prog Polym Sci 2007;32(8-9):991-1007 (Pubitemid 47198292)
99. Szybala C, Pritchard EM, Wilz A, et al. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol 2009;219:126-35
100. Li T, Steinbeck JA, Lusardi T, et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 2007;130(Pt 5):1276-88 (Pubitemid 47355953)
101. Theofilas P, Brar S, Stewart K-A, et al. Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. Epilepsia 2011;52(3):589-601